Lilly joins molecular glue field with Magnet deal worth up to $1.25B
Another day, another molecular glue deal in the biopharma world. This time around, it’s Eli Lilly partnering with the private startup Magnet Biomedicine on the technology. Lilly will pay up to $40...
View ArticlePfizer vet William Pao’s next venture; Sanofi’s computational science exec...
William Pao, a longtime R&D leader at Roche who briefly held the chief development officer post at Pfizer until the summer of 2023, has been stealthily leading a biotech ...
View ArticleTrump’s science crackdown hits rare disease research: ‘We need to sit down...
Jill Wood had pinned her hopes on a little-known federal program to fund her son’s gene therapy. The initiative, which awards vouchers to companies targeting rare pediatric diseases, offered her son a...
View ArticleBridgeBio oncology spinout to go public via combination with SPAC from...
The second blank-check vehicle from Cormorant's Bihua Chen plans to take BridgeBio's oncology spinout onto the Nasdaq. The special purpose acquisition company — known as Helix Acquisition Corp. II —...
View ArticlePacira absorbs GQ Bio for $32M; Layoffs at BMS, Eisai and CRISPR Therapeutics
Plus, news about Recursion, Nxera, Viatris and DualityBio: Pacira BioSciences takes on GQ Bio: The non-opioid pain biotech is spending $32 million to buy the remaining ...
View ArticlePraxis' essential tremor drug fails interim Phase 3 readout
Praxis reported that its lead small molecule program failed a Phase 3 study on Friday morning, sending its stock price {$PRAX} down roughly 40%. The company was studying whether an experimental drug...
View ArticleInfectious disease doctors consider 'mini-ACIP' if RFK erodes CDC vaccine panel
Infectious disease professionals, bracing for an overhaul of the CDC's vaccine advisory group, are in discussions to stand up a parallel committee of experts outside of government, Endpoints News has...
View ArticleCHMP recommends Regeneron, Novartis drugs that still await FDA approval
The European Medicines Agency’s human medicines committee (CHMP) has recommended four new drugs for approval, including Regeneron's Lynozyfic for the treatment of relapsed and refractory multiple...
View ArticleBipartisan 'pill penalty' fix and other bills vie for inclusion in...
Industry groups are looking to push government drug price negotiation and PBM reforms into a massive Republican domestic policy bill that will likely pass on party lines. PhRMA and a nonprofit ...
View ArticleAt least seven drugmakers say they will participate in round two of IRA...
More than half of drugmakers have agreed to participate in the second round of Medicare price negotiations amid ongoing legal battles and uncertainty surrounding the new administration’s stance on the...
View ArticleThe top 100 biotech investors; FDA vaccine meeting canceled; Can Bill...
Good morning and rabbit rabbit as we begin the month of March. It was another busy week in the world of biopharma so let’s jump straight into the headlines. John Carroll examined the last year ...
View ArticleICER finds GSK inhalers offer advantages over generics
The higher prices of two COPD inhalers from GSK that are targeted in the second round of government drug price negotiations are justified because of several advantages over generic competitors,...
View ArticleAfter Phase 3 depression setback, Neumora pauses two trials to make changes,...
Brain health biotech Neumora has stopped two of its Phase 3 trials in major depressive disorder to make adjustments after the first late-stage study unexpectedly failed at the beginning of this year....
View ArticleCallio emerges with $187M and ADCs from a decade-old Singapore biotech
Frazier Life Sciences and a cadre of well-known biotech investors are coming together for a new startup in the antibody-drug conjugates field, an area of cancer treatment R&D that has remained hot....
View ArticleNovo Nordisk signs $354M partnership with AI-guided biotech for ‘risky’ new...
Novo Nordisk has formed a $354 million research collaboration with Gensaic, the protein design company said on Monday, as the Danish pharma giant works to incubate new approaches in the metabolic ...
View ArticleGenentech's TNKase gets new approval; Sanofi gives up rights to oncology...
Plus, news about Nuvation Bio, Leqembi, IN8bio and Syros: Longtime clot-busting drug gets new approval: Roche and Genentech’s TNKase (tenecteplase) was approved Monday to treat acute ...
View ArticleNovartis licenses Kyorin’s preclinical chronic hives candidate for $55M upfront
Novartis is spending $55 million on global rights to Kyorin Pharmaceutical’s preclinical drug for inflammatory diseases in a deal that comes almost two decades after Novartis’ first pact with the...
View ArticleProtagonist, Takeda's profit sharing deal under spotlight after Phase 3 blood...
Protagonist Therapeutics reported a clean Phase 3 win on Monday for rusfertide — its rare blood disorder therapy — putting it on track for a fourth-quarter FDA submission. It also brings to the fore an...
View ArticleBiohaven’s ion channel drug fails pivotal bipolar mania study
Biohaven’s potassium channel drug has failed a late-stage study in bipolar mania, according to a statement in the company’s fourth-quarter earnings report. The Phase 2/3 study included an estimated 256...
View ArticlePliant calls it quits on Phase 2b IPF study
Pliant Therapeutics has officially discontinued a mid-stage study of its chronic lung disease treatment, less than a month after the trial's safety board recommended a halt. The South San Francisco...
View Article